Security
BIONEXUS GENE LAB CORP Common Stock · BGLCD
BGLCDOTCCommon stockHistorical · closed Jul 19, 2023CIK 1737523Updated Nov 16, 2026
BGLCD price & chart
This listing closed Jul 19, 2023. Live provider charts are shown only for current listings.
Current security: BGLC
About the company
BioNexus Gene Lab Corp. (Nasdaq: BGLC) is a technology-focused company operating across biotechnology, precision diagnostics and specialty materials. Through its subsidiaries, investments and licensing arrangements, the Company is developing new healthcare and life-science businesses alongside its established operations.
In the news
No coverage from other publishers is available.
Recent filings
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Regulation FD Disclosure
Items 1.01, 3.02, 7.01, 9.01
SCHEDULE 13D - filed by Tan Lee Su-Leng regarding BioNexus Gene Lab Corp
10-Q filing
Other Events
Items 8.01, 9.01
Other Events
Items 8.01, 9.01
Show 5 more recent filings
10-Q filing
10-K filing
NT 10-K filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Other Events
Items 8.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 7,621,228Source | 10,995,055Source | 8,726,423Source | 9,421,205Source | 11,139,727Source | 9,040,130Source | 9,479,939Source | 11,161,483Source | 9,252,784Source | 10,433,848Source | 11,399,793Source | 8,740,162Source |
| Property, Plant and Equipment, NetUSD | 1,570,584Source | 1,728,680Source | 1,537,800Source | 1,592,907Source | 1,347,600Source | 1,577,279Source | 1,520,279Source | 1,471,638Source | 1,598,769Source | 1,522,990Source | 1,511,618Source | 1,511,708Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | — | 1,232,658Source | — | — | — | — | — | 2,486,383Source | — | — | — |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 1,522,158Source | 1,425,343Source | 15,544Source | 1,852,085Source | 987,962Source | 79,860Source | 1,442,154Source | 839,558Source | 505,885Source | 1,376,571Source | 799,674Source | 2,868,364Source |
| Inventory, NetUSD | 1,007,448Source | 1,389,076Source | 652,892Source | 1,215,623Source | 1,033,003Source | 667,154Source | 1,179,144Source | 1,076,953Source | 676,703Source | 1,388,624Source | 1,137,770Source | 977,807Source |
| Assets, CurrentUSD | 5,626,802Source | 7,039,453Source | 4,943,409Source | 6,379,326Source | 7,842,869Source | 5,195,902Source | 6,542,389Source | 7,905,437Source | 5,448,738Source | 7,430,449Source | 8,046,800Source | 6,021,826Source |
| Operating Lease, Right-of-Use AssetUSD | 186,082Source | 232,747Source | 146,542Source | 200,284Source | 241,700Source | 163,113Source | 203,923Source | 128,176Source | 177,737Source | 215,243Source | 141,544Source | 55,730Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 804,966Source | 1,606,882Source | 947,981Source | 1,899,168Source | 1,593,973Source | 946,877Source | 1,708,303Source | 1,817,296Source | 637,856Source | 2,111,044Source | 1,741,941Source | 2,075,149Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 17,331,810Source | 17,332,315Source | 20,174,795Source | 17,331,810Source | 17,191,315Source | 20,174,795Source | 17,332,315Source | 17,191,315Source | 20,174,795Source | 17,332,315Source | 17,191,315Source | 10,929,574Source |
| Additional Paid in CapitalUSD | -5,011,891Source | -5,011,891Source | -5,011,891Source | -5,011,891Source | -5,011,891Source | -5,011,891Source | -5,011,891Source | -5,011,891Source | -5,011,891Source | -5,011,891Source | -5,011,891Source | -5,011,891Source |
| Retained Earnings (Accumulated Deficit)USD | -5,391,110Source | -3,094,301Source | -7,257,253Source | -4,682,119Source | -1,748,931Source | -6,970,802Source | -4,065,947Source | -1,948,035Source | -6,427,227Source | -3,442,620Source | -1,844,278Source | 1,156,392Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -112,547Source | -162,050Source | -127,209Source | -115,763Source | -884,739Source | -98,849Source | -482,841Source | -887,202Source | -120,749Source | -555,000Source | -677,294Source | -409,062Source |
| Stockholders' Equity Attributable to ParentUSD | 6,816,262Source | 9,388,173Source | 7,778,442Source | 7,522,037Source | 9,545,754Source | 8,093,253Source | 7,771,636Source | 9,344,187Source | 8,614,928Source | 8,322,804Source | 9,657,852Source | 6,665,013Source |
| Liabilities and EquityUSD | 7,621,228Source | 10,995,055Source | 8,726,423Source | 9,421,205Source | 11,139,727Source | 9,040,130Source | 9,479,939Source | 11,161,483Source | 9,252,784Source | 10,433,848Source | 11,399,793Source | 8,740,162Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 678,023Source | 1,414,869Source | 812,938Source | 1,757,821Source | 1,399,358Source | 796,470Source | 1,560,363Source | 1,716,534Source | 520,957Source | 1,951,303Source | 1,630,923Source | 2,004,077Source |
| Operating Lease, Liability, CurrentUSD | 56,803Source | 48,214Source | 56,677Source | 55,809Source | 53,210Source | 58,251Source | 52,173Source | 32,508Source | 59,147Source | 50,816Source | 34,632Source | 16,569Source |
| Accounts Payable, CurrentUSD | — | 1,033,125Source | — | — | 954,785Source | — | 1,182,723Source | 1,429,162Source | — | 1,503,326Source | 1,402,180Source | 1,861,015Source |
| Operating Lease, Liability, NoncurrentUSD | 126,943Source | 178,367Source | 89,350Source | 141,347Source | 182,697Source | 103,802Source | 147,940Source | 88,846Source | 116,899Source | 159,741Source | 98,763Source | 40,206Source |
| Deferred Income Tax Liabilities, NetUSD | 0Source | 13,646Source | — | 0Source | 11,918Source | — | 0Source | 11,916Source | — | 0Source | 12,255Source | 30,866Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | — | — | 70,469Source | — | — | 108,552Source | — | — | 126,036Source | — | — | — |
| Deferred Tax Liabilities, NetUSD | 0Source | 13,646Source | — | 0Source | 11,918Source | — | 0Source | 11,916Source | — | 0Source | 12,255Source | 30,866Source |
| Commitments and Contingencies | — | — | —Source | — | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -708,991Source | -1,345,370Source | — | -616,172Source | -543,575Source | -623,327Source | -2,984,607Source | 1,598,342Source | -2,629,043Source | -355,966Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | — | —Source | — | —Source | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | — | — | 794,770Source | — | — | — |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -9,549Source | -209,480Source | -711,921Source | — | -160,387Source | 544,108Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 12,305Source | — | -3,898Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -147,671Source | -824,072Source | -1,838,382Source | -2,234,260Source | -1,301,595Source | 544,028Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -13,988Source | -15,646Source | 944,751Source | 418,202Source | -382,576Source | -450,498Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 325Source | 9,052Source | 36,971Source | 226,989Source | 18Source | 54,171Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | — | — | — | 141,000Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 59,709Source | -860Source | 298,841Source | 144,975Source | 5,754,322Source | 115,962Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -88,406Source | -797,528Source | -400,583Source | -1,630,744Source | 3,810,472Source | -5,055Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 1,153,121Source | 4,137,219Source | 2,391,945Source | 1,537,189Source | 1,337,554Source | 2,089,438Source | 2,383,369Source | 2,886,966Source | 5,929,336Source | 2,118,864Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 269Source | 1,545Source | 6,865Source | 9,351Source | — | 12,479Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 0Source | -4,924Source | -14,823Source | -40,380Source | -66,973Source | -170,447Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | 13,544Source | 43,050Source | 194,207Source | 40,339Source | -259,679Source | -214,547Source |
| Additional Financial Items | ||||||||||||
| AmortizationUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | — | — | — |
| Deferred Other Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 12,305Source | 17,359Source | 3,898Source |
| DepreciationUSD | — | — | — | — | — | — | 28,293Source | 26,642Source | 111,873Source | 104,160Source | 83,253Source | 91,427Source |
| Disposal Group, Not Discontinued Operation, Gain (Loss) on DisposalUSD | — | — | — | — | — | — | — | — | — | — | -26,146Source | — |
| Equity Method Investment, Realized Gain (Loss) on DisposalUSD | — | — | — | — | — | — | — | — | 27,201Source | — | — | — |
| Equity Securities, FV-NI, Gain (Loss)USD | — | — | 0Source | 69,766Source | 0Source | 23,742Source | 0Source | 4,514Source | 0Source | 69,476Source | — | — |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | — | — | — | — | — | — | 0Source | -63,983Source | -93,965Source | — | — | — |
| Financing Interest ExpenseUSD | — | — | 6,482Source | 6,193Source | 4,055Source | 4,879Source | 3,085Source | 4,909Source | 19,542Source | 21,146Source | — | — |
| Gain (Loss) on Termination of LeaseUSD | — | — | — | — | — | — | — | 1,384Source | 0Source | 1,384Source | — | — |
| General and Administrative ExpenseUSD | — | — | 445,691Source | 792,413Source | 298,526Source | 516,790Source | 327,669Source | 391,876Source | 1,535,452Source | 1,973,968Source | 4,409,122Source | 1,729,489Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 1,555Source | 0Source | 0Source | 0Source | 0Source | 0Source | -3,494Source | -21,526Source | -52,310Source |
| Inventory Write-downUSD | — | — | — | — | — | — | — | — | — | — | 424Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -708,991Source | -1,345,370Source | -286,451Source | -616,172Source | -543,575Source | -623,327Source | -2,984,607Source | -1,598,342Source | -2,629,043Source | -355,966Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -708,991Source | -1,345,370Source | — | -616,172Source | -543,575Source | -623,327Source | -2,984,607Source | -1,598,342Source | — | — |
| Operating ExpensesUSD | — | — | 1,187,954Source | 2,129,685Source | 416,383Source | 1,188,776Source | 597,386Source | 1,053,331Source | 4,482,399Source | -4,935,696Source | — | — |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | 18,405Source | 16,743Source | 69,111Source | 60,778Source | 5,613Source | 4,913Source |
| Other Interest and Dividend IncomeUSD | — | — | 4,192Source | 38,826Source | — | 8,626Source | 0Source | 8,934Source | 22,112Source | 68,130Source | — | — |
| Other Nonoperating Income (Expense)USD | — | — | 107,760Source | 465,527Source | — | 209,461Source | 57,686Source | 91,420Source | 432,117Source | 2,072,473Source | — | — |
| Financing Receivable, Credit Loss, Expense (Reversal)USD | — | — | -175,818Source | -2,374Source | — | — | -202,497Source | -40,124Source | -271,211Source | -883,533Source | — | — |
| Revenue from Contract with Customer, Including Assessed Tax | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 2,543,823Source | 2,630,376Source | 76,156Source | 2,260,253Source | 22,842Source | 2,137,075Source | 7,424,911Source | 9,510,646Source | 9,770,806Source | 10,928,707Source |
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Operating Income (Loss)USD | — | — | -702,509Source | -1,337,622Source | -282,396Source | -611,293Source | -540,490Source | -618,418Source | -2,965,065Source | -1,573,702Source | -2,593,588Source | -291,177Source |
| Other Nonoperating Income (Expense)USD | — | — | 107,760Source | 465,527Source | — | 209,461Source | 57,686Source | 91,420Source | 432,117Source | 2,072,473Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -708,991Source | -1,343,815Source | -286,451Source | -616,172Source | -543,575Source | -623,327Source | -2,984,607Source | -1,594,848Source | -2,607,517Source | -303,656Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 1,555Source | 0Source | 0Source | 0Source | 0Source | 0Source | -3,494Source | -21,526Source | -52,310Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -708,991Source | -1,345,370Source | -286,451Source | -616,172Source | -543,575Source | -623,327Source | -2,984,607Source | -1,598,342Source | -2,629,043Source | -355,966Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.4Source | -0.75Source | -0.12Source | -0.34Source | -0.23Source | -0.35Source | — | -0.09Source | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 1,796,597Source | 1,796,766Source | 2,417,314Source | 1,796,597Source | 2,417,314Source | 1,796,766Source | — | 17,818,483Source | — | — |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | 0Source | 0Source | 0Source | — | — | — |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | — | — | — | — | — | — | 0Source | -63,983Source | -93,965Source | — | — | — |
| Financing Interest ExpenseUSD | — | — | 6,482Source | 6,193Source | 4,055Source | 4,879Source | 3,085Source | 4,909Source | 19,542Source | 21,146Source | — | — |
| General and Administrative ExpenseUSD | — | — | 445,691Source | 792,413Source | 298,526Source | 516,790Source | 327,669Source | 391,876Source | 1,535,452Source | 1,973,968Source | 4,409,122Source | 1,729,489Source |
| Gross ProfitUSD | — | — | 377,685Source | 326,536Source | 12,982Source | 368,022Source | -790Source | 343,493Source | 1,085,217Source | 1,289,521Source | 1,329,498Source | 1,259,029Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | — | — | — | -303,656Source |
| Interest ExpenseUSD | — | — | — | 6,193Source | — | — | — | — | — | — | 13,929Source | — |
| Interest Income (Expense), NetUSD | — | — | — | — | — | — | — | — | — | — | 8,877Source | — |
| Interest Income, OtherUSD | — | — | 20,778Source | 35,022Source | 21,183Source | 29,768Source | 17,179Source | 23,568Source | 83,888Source | 147,641Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -708,991Source | -1,345,370Source | — | -616,172Source | -543,575Source | -623,327Source | -2,984,607Source | -1,598,342Source | — | — |
| Operating ExpensesUSD | — | — | 1,187,954Source | 2,129,685Source | 416,383Source | 1,188,776Source | 597,386Source | 1,053,331Source | 4,482,399Source | -4,935,696Source | — | — |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | 18,405Source | 16,743Source | 69,111Source | 60,778Source | 5,613Source | 4,913Source |
| Other General and Administrative ExpenseUSD | — | — | 445,691Source | 792,413Source | — | 516,790Source | — | 391,876Source | 1,535,452Source | 1,973,968Source | 4,409,122Source | 1,729,489Source |
| Other IncomeUSD | — | — | 40,414Source | 43,127Source | 8,393Source | 77,566Source | 8,147Source | 29,251Source | 59,485Source | 59,405Source | 486,036Source | 179,283Source |
| Other Interest and Dividend IncomeUSD | — | — | 4,192Source | 38,826Source | — | 8,626Source | 0Source | 8,934Source | 22,112Source | 68,130Source | — | — |
| Research and Development ExpenseUSD | — | — | 14,876Source | 10,442Source | 13,671Source | 12,557Source | 14,487Source | 12,139Source | 50,670Source | 47,511Source | — | — |
| Selling and Marketing ExpenseUSD | — | — | 551,569Source | 1,245,456Source | 36,022Source | 608,427Source | 52,733Source | 540,695Source | 1,736,331Source | 2,030,684Source | — | — |
| Revenue from Contract with Customer, Including Assessed Tax | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
Filing attachments
bglc_ex991.htm · 8-K · 2026-10-07
EXHIBIT 99.1 BioNexus to Build AI Applications for Malaysian Healthcare Under Exclusive CogniAI Licence Licence of up to 20 years, payable in shares, as Malaysia commits RM1 billion to digitalizing public healthcare KUALA LUMPUR, Malaysia, October 7, 2026 - BioNexus Gene Lab Corp. (Nasdaq: BGLC) ("Company" or "BGLC") today announced plans to build AI applications for Malaysian healthcare, following the signing of a definitive agreement with Ruanyun Edai Technology Inc. (Nasdaq: RYET) on Octob…
Read attachment ↗bglc_ex991.htm · 8-K · 2026-07-28
EX-99.1 2 bglc_ex991.htm PRESS RELEASE bglc_ex991.htm EXHIBIT 99.1 FOR IMMEDIATE RELEASE BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit Meetings in Shanghai and Changzhou link VitaGuard's commercial use in China with BioNexus' Southeast Asian plans and Fidelion's international licensing efforts KUALA LUMPUR, Malaysia, July 28, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”) today announced continued progres…
Read attachment ↗bglc_ex991.htm · 8-K · 2026-06-05
EX-99.1 2 bglc_ex991.htm PRESS RELEASE bglc_ex991.htm EXHIBIT 99.1 BioNexus Gene Lab Corp. Calls for Malaysia - China Biotechnology Cooperation to Move Beyond Trade into Co-Development KUALA LUMPUR, Malaysia, May 29, 2026 - BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), a technology-focused company advancing innovation across biotechnology, precision diagnostics, and emerging healthcare platforms, today highlighted its participation in the 2026 China - Malaysia Econ…
Read attachment ↗bglc_ex991.htm · 8-K · 2026-03-17
EX-99.1 2 bglc_ex991.htm PRESS RELEASE bglc_ex991.htm EXHIBIT 99.1 FOR IMMEDIATE RELEASE BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of its VitaGuard™ MRD Platform KUALA LUMPUR, MALAYSIA - March 11, 2026 BioNexus Gene Lab Corp. (NASDAQ: BGLC) today announced that, in connection with its Fidelion Diagnostics Pte. Ltd (“Fidelion”) transaction, Dr. Muthu Meyyappan has been appointe…
Read attachment ↗bglc_ex991.htm · 8-K · 2026-02-23
EX-99.1 2 bglc_ex991.htm PRESS RELEASE bglc_ex991.htm EXHIBIT 99.1 FOR IMMEDIATE RELEASE BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman Enhanced board oversight aligns subsidiary with disciplined capital allocation and strategic evaluation framework KUALA LUMPUR, Malaysia - February 23, 2026 - BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), today announced the completion of a governance restructuring of its …
Read attachment ↗bglc_ex991.htm · 8-K · 2026-02-03
EXHIBIT 99.1 FOR IMMEDIATE RELEASE BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN’s Multi-Billion Dollar Market Kuala Lumpur, Malaysia - January 28, 2026 - BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), a technology-driven precision diagnostics company, today announced the formal commencement of its 2026 Deployment Phase for the VitaGuard™ Minimal Residual Disease (MRD) platform. Thi…
Read attachment ↗